SCHEMBL13735573

SCHEMBL13735573

ClCc1ccc(-c2ncccc2Cl)nn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.37
ALDH1A1 P00352 3/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
PKM P14618 1/20 0.33
HPGD P15428 1/20 0.33
ALOX15 P16050 1/20 0.33
HTT P42858 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CNR2 P34972 1/20 0.33
TDP1 Q9NUW8 1/20 0.32
S100A4 P26447 1/20 0.32
CDC25B P30305 1/20 0.32
MAPT P10636 1/20 0.31
KCNA5 P22460 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13735139 0.82 GABRG2 (0.39) ALDH1A1L3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL13735849 0.78 KDM4E (0.40) DPP4ALDH1A1KDM4E
SCHEMBL13736471 0.77 NPC1 (0.38) ALDH1A1L3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL13734681 0.76 DPP4 (0.36) DPP4ALDH1A1L3MBTL1NPC1RAB9A
SCHEMBL13734369 0.74 KDM4E (0.67) ALDH1A1L3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL30948306 0.74 KDM4E (0.67) ALDH1A1L3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL13734509 0.74 ALDH1A1 (0.49) DPP4ALDH1A1L3MBTL1NPC1RAB9A
SCHEMBL2306238 0.71 DPP4 (0.48) DPP4L3MBTL1KDM4ELMNACNR2
SCHEMBL8688609 0.69 DPP4 (0.47) DPP4L3MBTL1KDM4ELMNACNR2
SCHEMBL4633189 0.69 DPP4 (0.47) DPP4L3MBTL1KDM4ELMNACNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9187486-B2 Bicyclic pyridazine compounds as Pim inhibitors AMGEN INC. (US) 2015-11-17 US disclosed
US-9187486-B2 Bicyclic pyridazine compounds as Pim inhibitors AMGEN INC. (US) 2015-11-17 US disclosed
US-9187486-B2 Bicyclic pyridazine compounds as Pim inhibitors AMGEN INC. (US) 2015-11-17 US disclosed
US-20140221344-A1 Bicyclic Pyridazine Compounds as PIM Inhibitors AMGEN INC. 2014-08-07 US disclosed
US-20140221344-A1 Bicyclic Pyridazine Compounds as PIM Inhibitors AMGEN INC. 2014-08-07 US disclosed
US-20140221344-A1 Bicyclic Pyridazine Compounds as PIM Inhibitors AMGEN INC. 2014-08-07 US disclosed
EP-2702063-A1 BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS Amgen Inc. (US) 2014-03-05 EP disclosed
WO-2012148775-A1 BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-11-01 WO disclosed
WO-2012148775-A1 BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221344-A1 Bicyclic Pyridazine Compounds as PIM Inhibitors PIM1, PIM2, PIM3 DPP4 787/4885ALDH1A1 719/4885L3MBTL1 2307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.